GSK pays Synta $15M in milestone fees for cancer drug

12/15/2008 | Boston Globe (tiered subscription model), The

Synta Pharmaceuticals got $15 million in milestone fees from GlaxoSmithKline in a collaboration to develop and market elesclomol, an experimental drug designed to destroy cancer cells. Under the deal, Synta is entitled to a total payment of $585 million for reaching clinical-testing goals or making regulatory submissions.

View Full Article in:

Boston Globe (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Columbus, OH
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC